BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Events

  Science of Stability (SOS) BIO

  SOS BIO delves into mechanistic aspects for critical quality changes during shelf life and methodologies for advanced accelerated stability modeling for mAbs, peptides, ADCs, and oligonucleotides.

  August 6, 2025
• 

  Greg Chow

  August 6, 2025
• 

  China

  Big Pharma Provides Lifeline to Chinese Companies Struggling To Survive

  Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is only scratching at the surface of partnership-ready biotechs in the region.

  August 6, 2025

   · 

  7 min read

   · 

  Leslie Zhen Liang
• 

  Opinion

  How AI Can Help Pharma Companies Adapt to Policy Pressures

  The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market depends on mounting an agile response.

  August 6, 2025

   · 

  5 min read

   · 

  Jesse Mendelsohn
• 

  Vaccines

  RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA

  The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA vaccine development, a move that will affect several pharma companies, including Moderna, Pfizer, Sanofi and AstraZeneca.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  BioNTech Cuts 90 Jobs Amid ‘Strategic Alignment’

  BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing operations in Gaithersburg, Maryland.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Biopharma CEOs Can’t Dodge Policy Questions as Trump Lobs Wrench into Earnings Season

  From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

  August 6, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Tariffs

  Trump Threatens Highest Pharma Tariffs So Far at 250%

  President Donald Trump plans to start with a “small tariff” on pharmaceutical imports before ramping duties up to 250% within a year and a half.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  ‘Execution, Execution, Execution’: Novo’s New CEO Doubles Down on Obesity, Diabetes and Trims Pipeline

  Maziar Mike Doustdar, who was named as Novo Nordisk’s new CEO last week, spoke on a second quarter earnings call of reallocating resources to the company’s “main core” of metabolic disease.

  August 6, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

  Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.

  August 6, 2025

   · 

  2 min read

   · 

  Annalee Armstrong